[Coronarodilating properties of the GABA cyclic derivative TZ-146].
Galenko-Iaroshevskiĭ
P A
PA
Uvarov
A V
AV
Sheĭkh-Zade
Iu R
IuR
Cherednik
I L
IL
Popov
P B
PB
Sirotenko
D V
DV
D000262:Adenylyl Cyclases / Q000096:biosynthesis; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002415:Cats; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects*; D004285:Dogs; D004789:Enzyme Activation; D018756:GABA Antagonists / Q000494:pharmacology; D006439:Hemodynamics / Q000187:drug effects; D066298:In Vitro Techniques; D018727:Muscarinic Antagonists / Q000494:pharmacology; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000187:drug effects; D026941:Sodium Channel Blockers; D014628:Vagotomy; D014665:Vasodilator Agents / Q000494:pharmacology*; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*
D000317:Adrenergic alpha-Antagonists; D002121:Calcium Channel Blockers; D018756:GABA Antagonists; D018727:Muscarinic Antagonists; D011448:Prostaglandin Antagonists; D011963:Receptors, GABA-A; D026941:Sodium Channel Blockers; D014665:Vasodilator Agents; D005680:gamma-Aminobutyric Acid; D000262:Adenylyl Cyclases